UCB Turkey

Last updated: 25.05.2015

UCB_LOGO_TAG_C_RGB_vUCB, a biopharmaceutical company, focuses on the discovery and development of medicines and solutions for people living with severe diseases of the immune system or of the central nervous system in Belgium and internationally. The company’s core products include Cimzia for Crohn’s disease, rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis/ankylosing spondylitis; Vimpat for the treatment of epilepsy partial-onset seizures (POS); and Neupro for Parkinson’s disease and restless legs syndrome. It also offers Keppra for epilepsy POS, epilepsy primary generalized tonic-clonic seizures (PGTCS), and epilepsy myoclonic seizures; Zyrtec and Xyzal for allergy; Metadate for attention deficit and hyperactivity disorders; Nootropil for the treatment of psycho-organic syndromes or cognitive decline and cortical myoclonus; and Xyrem for narcolepsy with cataplexy in adult patients. In addition, the company provides Tussionex for relief of cough and upper respiratory symptoms associated with allergy or a cold; and Lortab for the relief from pain. UCB S.A. was founded in 1928 and is headquartered in Brussels, Belgium.

UCB products have been on the Turkish market since 1960, through the Turkish distributor Bilim. After 30 years, UCB Turkey was founded in 1990 with operations beginning in 1992.

Contact Details
Palladium Tower, Barbaros Mah.
Kardelen Sokak , No:2 Kat:24/80
34746 Ataşehir, İstanbul
Tel: +90 216 538 0000
Fax: +90 216 538 0009
E-mail:  tr-bilgi@ucb.com

Website: www.ucb.com.tr


We use cookies to ensure that we give you the best experience on our site. For more info

See our Cookie Privacy Policy Here